@BioWorld profile picture
BioWorld @BioWorld

Biopharma’s trusted news source

Joined April 2009
  • Tweets 47,475
  • Following 8,864
  • Followers 38,695
388 Photos and videos
Pinned Tweet
BioWorld
@BioWorld
Feb 2
Read the top updates in medical technologies, therapeutics & clinical development news on BioWorld. Explore BioWorld now: bioworld.com/articles/topic/… #LifeSciences #MedTech #MedicalTechnologies
1
2
2,182
China partnerships drive biopharma’s biggest deal month since 2023 bioworld.com/articles/731814 #biopharma @bmsnews @pfizer @Merck

China partnerships drive biopharma’s biggest deal month since 2023

Biopharma deal value through the first five months of 2026 reached $135.36 billion, outpacing every prior year and topping 2025’s previous high of $103.92 billion. May was the year’s biggest month so...

bioworld.com
334
Street canvu @MBXBio phase II HP data more than one way bioworld.com/articles/731813 #biopharma #hypoparathyroidism

Street canvu MBX phase II HP data more than one way

With full phase II results in hand, MBX Biosciences Inc. backers are stacking the odds of parathyroid hormone (PTH) peptide prodrug canvuparatide (canvu) against Yorvipath (palopegteriparatide} from...

bioworld.com
314
Industry calls for greater competitiveness incentives in EU Biotech Act bioworld.com/articles/731815 #biopharma @EFPIA

Industry calls for greater competitiveness incentives in EU Biotech Act

The industry is in support of the EU Biotech Act but says it needs to go further to restore Europe’s competitive position in biopharma. Instead of incremental adjustments, there should be wide-rang...

bioworld.com
266
Oricell brings first pivotal-stage CAR T in liver cancer bioworld.com/articles/731817 #biopharma #biopharma #CART #livercancer

Oricell brings first pivotal-stage CAR T in liver cancer

Oricell Therapeutics Holdings Ltd.’s glypican-3 (GPC3)-targeted autologous CAR T therapy, Ori-C101, is heading into a confirmatory registration phase II trial in patients with GPC3-positive advanced...

bioworld.com
1
3
384
.@TakedaPharma’s zasocitinib bests Sotyktuin phase III psoriasis trial (free w/one-time registration) bioworld.com/articles/731816 #biopharma #psoriasis #TYK2 #clinical

Takeda’s zasocitinib bests Sotyktu in phase III psoriasis trial

Takeda Pharmaceutical Co. Ltd.’s oral TYK2 inhibitor zasocitinib (TAK-279) demonstrated statistical superiority over Bristol Myers Squibb Co.’s first-in-class Sotyktu (deucravacitinib) in a top-line...

bioworld.com
1
377
BioWorld retweeted
BioWorld Science@BioWorldScience
Jun 12
#EHA2026: With new lenses, a changing view on pediatric cancers (free w/ registration) #preclinical #research #science #news bioworld.com/articles/731957…

EHA 2026: With new lenses, a changing view on pediatric cancers

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into cancer cells,” Franck Bourdeaut told...

bioworld.com
1
330
Another FDA no for #Camurus’ monthly acromegaly drug Oclaiz bioworld.com/articles/731805 #biopharma #regulatory #acromegaly #CRL

Another FDA no for Camurus’ monthly acromegaly drug Oclaiz

In a repeat move, the U.S. FDA issued yet again a complete response letter (CRL) to Camurus AB for its subcutaneous extended-release injection drug CAM-2029 (octreotide) to treat the rare chronic...

bioworld.com
1
501
EY report: Biopharma is balancing record growth and mounting pressures bioworld.com/articles/731804 #biopharma #deals @EYnews

EY report: Biopharma is balancing record growth and mounting pressures

The biotech industry delivered another year of strong headline performance in 2025, yet beneath the surface, a growing divide between the industry’s haves and have-nots is reshaping every dimension...

bioworld.com
3
404
#Ethyreal launches to treat the underlying cause of #Graves', #TED bioworld.com/articles/731803 #biopharma #newco #financing

Ethyreal launches to treat the underlying cause of Graves’, TED

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone receptor, at the Endocrine Society’s...

bioworld.com
2
429
#Enliven’s phase I #CML data Enable phase III with BCR/ABL1 bid (free w/one-time registration) bioworld.com/articles/731799 #biopharma #leukemia #cancer

Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive updated phase I data from the Enable...

bioworld.com
2
397
.@DermaSensor receives CE mark for skin cancer detection device bioworld.com/articles/731800 #medtech #skincancer

Dermasensor receives CE mark for skin cancer detection device

Dermasensor Inc. received CE mark approval for its handheld skin cancer detection device using spectroscopy and AI to test suspicious skin lesions for cancer in real time at the point of care. The...

bioworld.com
2
353
Laekna licenses LAE-118 ex-China to Vasque in $527M deal bioworld.com/articles/731802 #biopharma #deal #cancer #metabolicdisease

Laekna licenses LAE-118 ex-China to Vasque in $527M deal

Laekna Inc. is handing ex-China rights to internally discovered PI3Kα pan-mutant selective inhibitor LAE-118 to U.S.-based Vasque Bio Inc. in a deal worth up to $527 million, marking another asset-...

bioworld.com
1
397
China clears Alphamab’s HER2 bispecific antibody in gastric cancer bioworld.com/articles/731801 #biopharma #approval #China #gastriccancer #breastcancer

China clears Alphamab’s HER2 bispecific antibody in gastric cancer

China’s National Medical Products Administration has approved Suzhou Alphamab Co. Ltd.’s HER2 bispecific antibody, anbenitamab (KN-026), through priority review for adults with locally advanced or...

bioworld.com
407
Europe’s @AlzeCure, @OrionisBio in $1B #deals with @EliLillyandCo , @Novartis bioworld.com/articles/731722… #biopharma #molecularglue

Europe’s Alzecure, Orionis in $1B deals with Lilly, Novartis

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as to advance a preclinical Alzheimer’s...

bioworld.com
491
.@sanofi phase III #CIDP quit dents Dianthus; C1 mismatch? bioworld.com/articles/731720… #biopharma #polyneuropathy

Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by competitor Sanofi SA, which said that the...

bioworld.com
424
#ParabilisMedicines takes top spot, pricing largest biopharma #IPO at $670M (free w/one-time registration bioworld.com/articles/731719… #financing #oncology

Parabilis takes top spot, pricing largest biopharma IPO at $670M

Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed it. The oncology-focused firm priced...

bioworld.com
1
436
Three deals in six days: Everest builds late-stage APAC portfolio bioworld.com/articles/731721… #biopharma #China #APAC #licensing #dealmaking

Three deals in six days: Everest builds late-stage APAC portfolio

Fresh off a deal with Travere Therapeutics Inc. for civorebrutinib worth more than $1.14 billion, Everest Medicines Ltd. went on a shopping spree, striking three deals in six days to expand its...

bioworld.com
323
Researchers hit back after colleagues removed from @AmDiabetesAssn meeting bioworld.com/articles/731723… #biopharma #diabetes #science #ADASciSessions @AmDiabetesAssn

Researchers hit back after colleagues removed from ADA meeting

Former principal officers of the American Diabetes Association (ADA) have hit back at the association’s board and CEO after it prohibited the distribution of an editorial published in its flagship...

bioworld.com
1
397
Med-tech #IPO window holds with $1.51B raised through May in 2026 bioworld.com/articles/731709… #medtech @MobiaMedical @starsportsmed @ClearNoteHealth

Med-tech IPO window holds with $1.51B raised through May in 2026

Total med-tech financing through the first five months of 2026 reached $11.01 billion, falling between 2024’s $12.76 billion and 2023’s $8.95 billion over the same period, and trailing 2025’s $14.83...

bioworld.com
2
352
Columbia researchers use base editing to modify human embryo genome bioworld.com/articles/731708… #science #biopharma #baseediting

Columbia researchers use base editing to modify human embryo genome

Scientists at Columbia University have used base editing to make precise changes in the genomes of human embryos, avoiding the damage to chromosomes that occurs following two-stranded DNA cuts with...

bioworld.com
3
348
Load more